Abstract
miRNAs are small non-coding RNAs of ~24 nt that can block mRNA translation and/or negatively regulate its stability. There is a large body of evidence that dysregulation of miRNAs is a hallmark of cancer. miRNAs are often aberrantly expressed and their function is linked to the regulation of oncogenes and/or tumor suppressor genes involved in cell signaling pathway. miR-221 and miR-222 are two highly homologous microRNAs, whose upregulation has been recently described in several types of human tumors. miR-221/222 have been considered to act as oncogenes or tumor suppressors, depending on tumor system. Silencing oncomiRs or gene therapy approaches, based on re-expression of miRNAs that are down-regulated in cancer cells, could represent a novel anti-tumor approach for integrated cancer therapy. Here we will review the role of miR-221/222 in cancer progression and their use as prognostic and therapeutic tools in cancer.
Keywords: Cancer, cancer therpay, microRNA, transcription, Dicer, RNA-induced silencing complex (RISC), translation, genome, apoptotic pathways, metastasis, leukemia, lymphoma, hepatocellular carcinoma, oncogenes, oncosuppressor genes
Current Molecular Medicine
Title: miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy
Volume: 12 Issue: 1
Author(s): M. Garofalo, C. Quintavalle, G. Romano, C. M. Croce and G. Condorelli
Affiliation:
Keywords: Cancer, cancer therpay, microRNA, transcription, Dicer, RNA-induced silencing complex (RISC), translation, genome, apoptotic pathways, metastasis, leukemia, lymphoma, hepatocellular carcinoma, oncogenes, oncosuppressor genes
Abstract: miRNAs are small non-coding RNAs of ~24 nt that can block mRNA translation and/or negatively regulate its stability. There is a large body of evidence that dysregulation of miRNAs is a hallmark of cancer. miRNAs are often aberrantly expressed and their function is linked to the regulation of oncogenes and/or tumor suppressor genes involved in cell signaling pathway. miR-221 and miR-222 are two highly homologous microRNAs, whose upregulation has been recently described in several types of human tumors. miR-221/222 have been considered to act as oncogenes or tumor suppressors, depending on tumor system. Silencing oncomiRs or gene therapy approaches, based on re-expression of miRNAs that are down-regulated in cancer cells, could represent a novel anti-tumor approach for integrated cancer therapy. Here we will review the role of miR-221/222 in cancer progression and their use as prognostic and therapeutic tools in cancer.
Export Options
About this article
Cite this article as:
Garofalo M., Quintavalle C., Romano G., M. Croce C. and Condorelli G., miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy, Current Molecular Medicine 2012; 12 (1) . https://dx.doi.org/10.2174/156652412798376170
DOI https://dx.doi.org/10.2174/156652412798376170 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents
Current Medicinal Chemistry Electrical Impedance Scanning - A New Diagnostic Tool in Cancer Detection: Current Status and Recent Developments
Current Medical Imaging Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
Current Medicinal Chemistry Editorial [Hot Topic: Targeting the Microenvironment in Hematological Malignancies: How to Condition both Stromal and Effector Cells to Overcome Cancer Spreading(Guest Editors: Maria Raffaella Zocchi and Alessandro Poggi)]
Current Medicinal Chemistry The Role of Tumor Associated Macrophages in the Tumor Microenvironment: Mechanism and Functions
Anti-Cancer Agents in Medicinal Chemistry siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors
Drug Metabolism Letters Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Photosensitization of Biomolecules by Phenothiazine Derivatives
Current Drug Targets Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry Germinated Soybean Products as Nutraceutical Compounds in Breadmaking
Current Nutrition & Food Science Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry The Role of Micafungin and Anidulafungin in the Treatment of Systemic Fungal Infections: Applications and Patents for Two Novel Echinocandins
Recent Patents on Anti-Infective Drug Discovery Cerenkov Luminescence Imaging at a Glance
Current Molecular Imaging (Discontinued) Insertional Mutagenesis by Retroviral Vectors: Current Concepts and Methods of Analysis
Current Gene Therapy Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention
MicroRNA Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued)